Business
Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023
HOUSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing
About this update from Marker Therapeutics, Inc.
[{"type":"text","content":"HOUSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced participation in a live webcast produced by Demy-Colton and sponsored by the WBB Research Institute titled “Beyond CAR-T, What’s Next for Cell Therapy”. The virtual event is scheduled to take place on August 9, 2023, at 11:00 a.m. EDT. This discussion aims to bring together distinguished experts in the cell therapy arena to exchange ideas on current treatment options and challenges, and deliberate on the future direction of immunotherapies. During the one hour virtual event, featured panelists will provide an overview and discuss the limitations of CAR-T cell therapies. Panelists will also highlight the potential impact and unique merits of the multiple tumor-associated antigen (multiTAA) targeted therapy Marker is developing in comparison to single antigen targeted therapies. The event will feature renowned experts in the cancer field, whose contributions have significantly shaped the immuno-oncology research and broader healthcare environment: Helen E. Heslop, M.D., DSC, Professor of Medicine and Pediatrics and Director of the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist Hospital, and Texas Children’s Hospital.Malcolm K. Brenner, M.D., Ph.D., Founding Director of the Center for Cell and Gene Therapy and Fayez Sarofim Distinguished Service Professor at Baylor College of Medicine in the Departments of Medicine, Pediatrics, and Human and Molecular Genetics.Juan F. Vera, M.D., President and Chief Executive Officer, Marker TherapeuticsMark W. Frohlich, M.D., Chief Executive Officer, Indapta Therapeutics The extensive knowledge and unique perspectives of the panelists promises a profound and impactful discussion. Virtual Webcast Agenda INTRODUCTIONHelen E. Heslop, M.D. CAR-T CELLS AN OVERVIEW OF THE CURRENT LANDSCAPEChair: Querida Anderson, Editorial Director and Biopharma Expert Panelists: Helen E. Heslop, M.D.Malcolm K. Brenner, M.D., Ph.D. BEYOND CAR-T CELL THERAPYChair: Steve Brozak, Managing Partner and President of WBB Securities Panelists:Juan F. Vera, M.D.Mark W. Frohlich, M.D. Q&A SESSION The roundtable di...